A5074616087- Parkinson's Disease Mechanisms and Treatments
- Nuclear Receptors and Signaling
- Autism Spectrum Disorder Research
- Chronic Myeloid Leukemia Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Ethics and Social Impacts of AI
- Delphi Technique in Research
- Neurological disorders and treatments
- Ethics in Clinical Research
- Neuroethics, Human Enhancement, Biomedical Innovations
- Advanced Breast Cancer Therapies
- Privacy, Security, and Data Protection
- Coenzyme Q10 studies and effects
- Biotechnology and Related Fields
Parkinson's Foundation
2018-2024
Patient Advocate Foundation
2021
Stevens Institute of Technology
2020
Since 2020, annual reports on the clinical development of new drug-based therapies for neurodegenerative condition Parkinson's disease (PD) have been generated. These reviews followed progress both "symptomatic treatments" (ST - improves/reduces symptoms condition) and "disease modifying (DMT attempts to delay/slow progression by addressing underlying biology PD). Additional efforts made further categorize these experimental treatments based their mechanisms action class drug.A dataset...
There is a critical need for careful and independent validation of reported symptomatic efficacy dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD).To assess safety tolerability participants with moderately advanced PD. Secondary exploratory objectives were to its affect on PD disability, pharmacokinetics, cerebrospinal fluid (CSF) penetration, biomarkers.This was 6-month, multicenter, randomized parallel-group, double-blind, placebo-controlled trial. Recruitment...
Abstract Background Nilotinib, a tyrosine kinase Abelson inhibitor, exhibits neuroprotective effects in preclinical Parkinson disease (PD) models. Methods This Phase 2A double-blind placebo-controlled study moderate/advanced PD randomized participants 1:1:1 to placebo:150:300 mg nilotinib matching capsules once daily for 6 months. The primary outcomes were safety and tolerability, the latter defined as ability complete on assigned dose. Secondary included change disability (Movement Disorder...
Personal information, including health-related data, may be used in ways we did not intend when it was originally shared. However, the organizations that collect these data do always have necessary social license to use and share it. Although some technology companies published principles on ethical of artificial intelligence, foundational issue what is acceptable with just analytical tools manage it, has been fully considered. Furthermore, unclear whether input from public or patients...
Background: Design of disease modification (DM) trials for Parkinson’s (PD) is challenging. Successful delivery requires a shared understanding priorities and practicalities. Objective: To seek stakeholder consensus on phase 3 trials’ overall goals structure, inclusion criteria, outcome measures, trial understand where perspectives differ. Methods: An international expert panel comprising people with (PwP), care partners (CP), clinical scientists, representatives from industry, funders...
May 7, 2019April 9, 2019Free AccessNILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Design Status Update (P3.8-035)Tanya Simuni, Brian Fiske, Kalpana Merchant, Christopher Coffey, Helen Matthews, Richard K. Wyse, Patrik Brundin, … Show All , David Simon, Michael A. Schwarzschild, Weiner, Jamie Adams, Charles Venuto, Laura Trusso, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff FewerAuthors Info & AffiliationsApril 2019 issue92...
April 26, 2018April 10, 2018Free AccessA Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)Tanya Simuni, Brian Fiske, Kalpana Merchant, Christopher Coffey, Helen Matthews, Richard Wyse, Patrik Brundin, … Show All , Gary Rafaloff, David Simon, Michael Schwarzschild, Daivd Weiner, Charles Venuto, Laura Trusso FewerAuthors Info & AffiliationsApril 2018 issue90 (15_supplement) Letters to the Editor
Tuesday, April 28April 14, 2020Free AccessPharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib Patients with Moderate to Advance Parkinson’s Disease (4418)Kalpana Merchant, Tanya Simuni, Brian Fiske, Christopher Coffey, Helen Matthews, Richard Wyse, Patrik Brundin, … Show All , David Simon, Michael Schwarzschild, Weiner, Jamie Adams, Charles Venuto, Laura Trusso, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff FewerAuthors Info & AffiliationsApril 2020...
<sec> <title>BACKGROUND</title> Personal information, including health-related data, may be used in ways we did not intend when it was originally shared. However, the organizations that collect these data do always have necessary social license to use and share it. Although some technology companies published principles on ethical of artificial intelligence, foundational issue what is acceptable with just analytical tools manage it, has been fully considered. Furthermore, unclear whether...